Evidence Generation for JCAs: How Can AI Boost Efficiency and Maintain Quality?

October 16, 2024

Back to all webinars

Title: Evidence Generation for JCAs: How Can AI Boost Efficiency and Maintain Quality?

Wednesday, October 16, 2024
10:00AM EDT |2:00PM UTC | 4:00pm CEST

Click here for time zone conversion


Register Now

 

Description

This webinar will benefit stakeholders involved in health technology assessment (HTA), artificial intelligence (AI) development, and AI regulation by providing a comprehensive debate on the use of AI in Joint Clinical Assessments (JCAs). 

The moderator, Grace Fox, will open the panel by addressing the challenges of JCAs in the context of the European Union (EU) HTA process. Each of the panelists will be given 10 minutes to present their perspective. Farhad Shokraneh will discuss the current state of research on AI use in systematic literature reviews (SLRs), highlighting opportunities and challenges from an academic perspective. Susanne Hartz will discuss the industry perspective for including AI in the SLR process, highlighting efficiency gains and implementation challenges. Emanuele Arcà will provide the consulting perspective on the potential of AI to expedite SLRs and reflect on HTA stakeholder perceptions based on recent research by OPEN Health.

 

 

Learning Objectives

  • Starting in January 2025, as part of the EU HTA regulation, all new oncology and advanced therapy medicinal products will be subject to JCA. As stipulated in the JCA implementing act, SLR searches should be no older than three months, while the final scope of the JCA will only be issued 100 days prior to the submission deadline. This compacted timeline presents a challenge to ensure SLRs are conducted quickly while maintaining the rigor required for HTA. 
  • The integration of AI in SLRs presents an opportunity to improve the efficiency and accuracy of evidence generation for JCAs. This webinar will explore how AI can support evidence generation for JCA and consider the potential benefits and challenges.
  • Specifically, the webinar discussion will address the following key questions:
    • How can AI tools increase the efficiency of SLRs for JCAs while maintaining quality?
    • What are the possible challenges and barriers to implementing AI for SLRs?
    • What will it take for HTA organizations to accept AI-supported SLRs?
    • What steps can be taken to ensure appropriate, reliable, and transparent use of AI for preparing SLRs in the JCA context?

 

Moderator:

Grace Fox, PhD, Associate Director, Strategic Market Access, OPEN Health, Bethesda, MD, USA

 

Speakers:

Emanuele Arcà, MSc, Scientific Office Lead, Strategic Market Access, OPEN Health, Rotterdam, The Netherlands

Farhad Shokraneh, PhD, Evidence Synthesis Manager, Oxford University, Oxford, England, UK

Susanne Hartz, Dipl. Vw., Director, Global Health Outcomes/HTA International, Eli Lilly and Company, London, England, UK

 

 

 

Brought to you by: OPEN Health

 

Please note: On the day of the scheduled webinar, the first 1000 registered participants will be accepted into the webinar. For those who are unable to attend, or would like to review the webinar at a later date, the full-length webinar recording will be made available at the ISPOR Educational Webinar Series webpage approximately 2 days after the scheduled Webinar. Reservations are on a first-come, first-served basis.

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×